A fully-automated on-line oxidation column-switching HPLC system has been developed for the determination of endogenous melatonin in human plasma and saliva. This HPLC system consists of four processes. In the first step, melatonin is fractionated using a reversed-phase C4 column (Proteonavi, 75 mm × 1.0 mm i.d.). In the second step, the obtained melatonin fraction is on-line collected, and oxidized to a highly-fluorescent compound, N- [(6-methoxy-4-oxo-1,4-dihydroquinolin-3-yl)methyl]acetamide (6-MOQMA), by mixing with hydrogen peroxide under alkaline conditions. In the third step, the produced 6-MOQMA is concentrated, and the oxidation reagents are removed using an alkaline resistive reversed-phase column, Asahipak ODP (35 mm × 1.0 mm i.d.). In the final fourth step, the 6-MOQMA is determined by a microbore-ODS column packed with ultrafine particles (CAPCELL PAK C18 IF, 250 mm × 1.0 mm i.d.). The limit of detection of melatonin using this system is about 200 amol/injection, and the determination of endogenous melatonin in a small volume of human physiological fluids, such as 100 μL of plasma and 300 μL of saliva, was successfully accomplished.
Introduction
Melatonin, N-acetyl-5-methoxytriptamine, is a pineal hormone synthesized from L-tryptophan via serotonin and N-acetylserotonin. 1, 2 The synthesis and the secretion of melatonin, which is regulated by a light-dark signal and the enzymatic activity of serotonin-N-acetyltransferase, shows a clear circadian rhythm increasing during the night.
1,2 Melatonin thus transmits a light-dark signal to various brain [3] [4] [5] [6] and peripheral tissues 3, [7] [8] [9] [10] via blood circulation.
In the suprachaiasmatic nuclei, the melatonin receptor is also expressed, 11 and melatonin is reported to regulate the biological clock in this tissue. 3, 12 Recently, the life style in human society has become complicated, and rhythm disorders, such as obstructive sleep apnoea syndrome and non-24-hour sleep-wake syndrome, are increasing. 13, 14 For the treating these rhythm disorders, determining of the melatonin rhythm in each patient is expected as an indicator of individual biological rhythms. Evaluating the melatonin rhythm in each patient is also clinically useful for chronotherapy, which enhances the efficacy of the medicine and reduces the side effects by considering the biological rhythm. 15, 16 These therapies are being aggressively adopted in the treatment of cancer and asthma, and a suitable dose regimen is expected to be designed by analyzing the individual biological clocks. However, the amount of endogenous melatonin is extremely low, and a 1 -5 mL blood sample is needed for the determination of melatonin by the methods already reported. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] To obtain 1 -5 mL of blood, blood sampling from the cubital vein is normally required, and it is practically a severe task for patients to measure the circadian rhythm of melatonin (blood should be obtained 6 -8 times within one day). Therefore, a highly sensitive and selective analytical method, which can determine endogenous melatonin using 10 -100 μL of plasma (100 μL of plasma can be obtained by a less invasive method) is required.
The aim of the present study is to establish a highly sensitive and practically patient friendly analytical method for the determination of endogenous melatonin in human physiological fluids. Until now, various analytical methods have been reported for the determination of endogenous melatonin in human plasma/serum and saliva.
Radioimmunoassay (RIA), [18] [19] [20] enzyme-linked immunosorbent assay (ELISA), 21, 28 gas chromatography (GC) [22] [23] [24] and high-performance liquid chromatography (HPLC) [25] [26] [27] 29, 30 are frequently used. The melatonin rhythm in human plasma/serum and saliva has also been studied using these methods, and the amounts of melatonin are reported to be 3 to 10 pM in the diurnal period. The limit of detection of melatonin by these methods are around 5 fmol/ injection, therefore, a few mL of blood and saliva are needed. On the other hand, we have already reported a highly sensitive HPLC method for the determination of melatonin using precolumn oxidation and fluorescence detection. [31] [32] [33] [34] By this method, melatonin is converted to an oxidized compound, N-[ (6-methoxy-4-oxo-1,4-dihydroquinolin-3yl )methyl] acetamide (6-MOQMA, Fig. 1) , and the produced 6-MOQMA has a strong fluorescence emission at 382 nm with excitation at 246 nm. The limit of detection of melatonin using this precolumn oxidation method was 200 amol/injection using a semimicro-HPLC system. However, this method requires skillful techniques to obtain reproducible results, and also to reduce contamination from the environment; therefore, the development of a fully-automated on-line oxidation HPLC system is highly required as a practically useful method. In the present study, we developed a fully-automated on-line oxidation column-switching HPLC system, and the amount of endogenous melatonin in human clinical samples (plasma and saliva) has been determined.
Experimental

Materials
Melatonin was purchased from SIGMA (St. Louis, MO). Methanol (MeOH) and tetrahydrofuran (THF) of HPLC grade, ethanol (EtOH, dry, 99.5%) trifluoroacetic acid (TFA), sodium carbonate (Na2CO3) and aqueous hydrogen peroxide (H2O2, 31%, v/v) were obtained from Wako (Osaka, Japan). Acetonitrile (MeCN) of HPLC grade was obtained from Nacalai Tesque (Kyoto, Japan). Water was purified using Milli-Q Elix3 and Gradient A 10 systems (Merck Millipore, Billerica, MA). All other reagents were of guaranteed reagent grade and used without further purification.
Effect of organic solvents on the oxidation of melatonin
Melatonin was dissolved in water containing an organic solvent (MeOH, EtOH, MeCN or THF, concentration of the organic solvent was 1.2, 2.4, 6 or 12%). To a glass vial, 1.2 nM of the melatonin solution (100 μL), an aqueous 120 mM Na2CO3 solution (10 μL) and aqueous 1.2 mM H2O2 solution (10 μL) were added. The vial was tightly capped and heated at 100 C for 30 min; then, 20 μL of the reaction mixture was injected into a reversed-phase HPLC system. The HPLC system (NANOSPACE SI-2 series, Shiseido, Tokyo, Japan) consisted of a type 3009 degasser, a 3101 pump, a 3023 auto sampler, a 3004 column oven and a 3213 fluorescence detector. The analytical column was a CAPCELL PAK C18 MGII (75 mm × 2.0 mm i.d., 40 C, Shiseido), and the mobile phase was a MeCN-TFAwater (10:0.08:90, v/v, 200 μL/min). Fluorescence detection was carried out at 400 nm with excitation at 245 nm.
Establishment of an on-line oxidation unit
The on-line oxidation unit consisted of two 3101 pumps, a 3011 high-pressure valve and a 3019 thermo reactor (NANOSPACE SI-2 series, Shiseido). The flow diagram of the HPLC system used for the evaluation of this on-line oxidation unit is shown in Fig. 2 . The eluent of pump 1 was pure water. The reagent added from pump 2 was aqueous Na2CO3, and aqueous H2O2 was added from pump 3. The melatonin solution (10 nM, 50 μL) was injected from the auto sampler, and mixed with the aqueous Na2CO3 and H2O2 solutions. The mixture was introduced into the thermo reactor by switching high-pressure valve 1 and sealed by switching high-pressure valve 1 again, 
Sample preparation procedure of human physiological fluids
Human blood was collected in a heparinized tube (Nippon Becton Dickinson, Tokyo, Japan), and the plasma was obtained by centrifugation (12100g, 4 C) for 10 min. Saliva was directly collected in a clear tube. Aliquots of the plasma (100 μL) and saliva (300 μL) were applied to a solid-phase extraction cartridge (adande:l PEP0301, Shiseido) and washed with 5 mL of water. The retained components were then eluted by adding 300 μL of MeCN, and the eluate was dried. The residue was dissolved in 60 μL of water, and 50 μL of the solution was injected into the fully-automated on-line oxidation columnswitching HPLC system described in the following section.
A fully-automated on-line oxidation column-switching HPLC system
The fully-automated on-line oxidation column-switching HPLC system (NANOSPACE SI-2 series, Shiseido) consisted of a 3202 degasser, six pumps (3101 and 3001), a 3023 auto sampler, two 3004 column ovens, two 3213 fluorescence detectors, three high-pressure valves (3011 and 3012) and a 3019 thermo reactor with a reaction loop of 500 μL. The flow diagram is shown in Fig. 3 . The sample solution was injected from an auto sampler, and separated by a purification column (Proteonavi, 75 mm × 1.0 mm i.d., 60 C, Shiseido) using pure water as the mobile phase (100 μL min -1 ). Fluorescence detection of the melatonin was carried out at 350 nm with excitation at 278 nm, and the melatonin fraction was collected in a loop by switching high-pressure valve 1. The collected melatonin fraction was introduced into the thermo reactor by switching high-pressure valve 1 again (eluent of pump 3 was pure water, 100 μL min -1 ), and the derivatizing reagents (aqueous 25 mM Na2CO3 with the flow rate of 80 μL min -1 and aqueous 2 mM H2O2 with the flow rate of 20 μL min -1 ) were added from pumps 4 and 5. The thermo reactor was then tightly sealed by switching high-pressure valve 2, and the mixture was at 400 nm with excitation at 245 nm.
Results and Discussion
Effect of organic solvents on the oxidation of melatonin and selection of the purification column
For the determination of endogenous melatonin in a small clinical sample volume, a highly sensitive and selective analytical method is essential. For selective analysis, the online purification of melatonin in the physiological samples is effective, and the pre-column oxidation of melatonin to a highlyfluorescent compound, 6-MOQMA, is useful for sensitive determination. For the purification of melatonin in biological matrices using a reversed-phase column, some organic solvents are frequently used as the mobile phase additive; these organic solvents may affect the recovery of the on-line oxidation of melatonin. Therefore, purification columns and mobile phases used for the reversed-phase isolation of melatonin have been investigated. As the organic solvents, MeOH, EtOH, MeCN and THF were selected, and the effect of these solvents on the oxidation of melatonin was investigated. As a result, the oxidative reaction was severely affected by the addition of these organic solvents, and only sufficiently proceeded in aqueous solutions containing 0 -2% MeCN (Fig. 4) .
Therefore, mild reversed-phase columns, such as the CN, C1 and C4 columns, were examined as the purification column, because weak mobile phases (aqueous solutions containing 0 -2% MeCN) could be used for compatibility with the on-line oxidation. A C4 column showed a good separation, and the sufficient resolution of melatonin could be obtained compared to the CN and C1 columns. Based on these findings, a C4 column of 1.0 mm i.d. × 75 mm was used at 60 C. A semimicro column of 1.0 mm i.d. was used to inhibit the diffusion and to decrease the volume of the melatonin fraction; a column length of 75 mm and a temperature of 60 C were used for shortening the analytical time.
For the determination of melatonin by reversed-phase HPLC, several methods have already been reported. In these methods, a high concentration of organic solvents, such as 20 -50% of MeOH or MeCN, was required as the mobile phase. [25] [26] [27] 29, 30 However, melatonin could not be oxidized in these mobile phases containing a high concentration of organic solvents.
Therefore, in the present investigation, the solvents for the precolumn oxidation were thoroughly examined. It was found that the oxidative reaction sufficiently proceeded in aqueous solutions containing 0 -2% MeCN. By using aqueous 0 -2% MeCN as the mobile phase and a weak reversed-phase C4 column as the stationary phase, the purification of melatonin in human clinical samples could be successfully accomplished.
Design and establishment of an on-line oxidation unit
The oxidative conversion of melatonin to 6-MOQMA is useful for a highly sensitive analysis of melatonin. To establish a fully-automated system applying this concept, an on-line oxidation unit for the pre-column oxidation of melatonin is necessary. In the present study, we designed and developed the unit illustrated in Fig. 2 , and the on-line oxidation conditions were investigated. Melatonin was injected from the autosampler, mixed with oxidation reagents (H2O2 and Na2CO3) and introduced into the thermo reactor. The thermo reactor was tightly sealed by switching HPV1 and 2, and the on-line oxidation was carried out by heating the reactor. After the oxidation, 6-MOQMA formed by the reaction was trapped using the concentration column (Asahipak ODP, an alkaline resistant reversed-phase column) and the reagents were removed. The concentrated 6-MOQMA was then injected into the CAPCELL PAK C18 ACR column and determined by the fluorescence detector. The remaining melatonin could also be simultaneously determined by the same HPLC system. The reaction conditions were investigated by changing the concentrations of Na2CO3 and H2O2, the reaction temperature and the reaction time. The amount of 6-MOQMA increased along with the increasing concentrations of Na2CO3 and H2O2. However, the amount of 6-MOQMA decreased in the presence of excess Na2CO3 and H2O2. Concerning the reaction temperature, the oxidative reaction was effectively proceeded by increasing the temperature. However, 6-MOQMA was not stable in the reaction mixture with the temperatures above 120 C. As a result, 6-MOQMA was produced in good yield (around 80%) using 40 mM Na2CO3 and 0.8 mM H2O2 as the oxidation reagents, and heated at 110 C for 30 min. Figure 5 shows chromatograms of 6-MOQMA and melatonin with/without oxidation. Without oxidation, a clear peak of melatonin was observed at 25 min and 6-MOQMA was not present. On the other hand, the melatonin disappeared after oxidation, and a clear peak of 6-MOQMA was observed at 12 min.
In previous reports, we have already described the oxidation Fig. 4 Effect of organic solvents on the oxidation of melatonin. MeOH( ), EtOH ( ), MeCN ( ) or THF ( ) was added to the reaction mixture and the production of 6-MOQMA was monitored.
The peak height of 6-MOQMA obtained without the addition of organic solvent was taken as 100. of melatonin using Na2CO3 and H2O2 by an off-line reaction without purification of the melatonin. In these cases, different reaction conditions should be used for the standard melatonin and biological samples because the reaction is severely affected by the presence of biological matrices. The conditions for the standard melatonin were 25 mM Na2CO3 and 0.42 mM H2O2 (as the final concentrations) and heating at 90 C for 30 min. 31 On the other hand, for the oxidation of melatonin in biological matrices, 200 mM Na2CO3 and 5 mM H2O2 were used with heating at 100 C for 30 min. [32] [33] [34] In the present investigation, the same reaction conditions could be used for both the standard melatonin and biological samples (10 mM Na2O3 and 0.2 mM H2O2, heated at 110 C for 30 min) due to the utilization of the on-line purification of melatonin. In all of the samples (standard solution and biological matrices), a sufficient reaction yield was obtained, which is a significant advantage of the present system.
Development of a fully-automated on-line oxidation columnswitching HPLC system
According to the results shown above, a fully-automated online oxidation column-switching HPLC system was established. The flow diagram is illustrated in Fig. 3 . This system consists of four steps. In the first step, melatonin was fractionated using a C4 reversed-pahse column (Proteonavi, 75 mm × 1.0 mm i.d.), with pure water as the mobile phase. In the second step, the obtained melatonin fraction was on-line collected and oxidized to 6-MOQMA by mixing the reagents and heating at 110 C for 30 min. In the third step, the produced 6-MOQMA was concentrated by a short alkaline resistant C18 trapping column, and excess reagents were removed. 6-MOQMA was then introduced into the microbore-ODS column and sensitive determination was performed in the final fourth step. To develop a sensitive fully-automated HPLC system, a concentration column and an analytical column were investigated. As the concentration column, Asahipak ODP columns with different dimensions (1.0 mm × 35 mm, 1.0 × 50, 2.0 × 35, 2.0 × 50), were tested. As a result, the highly sensitive analysis of 6-MOQMA could be performed by an Asahipak ODP column of 1.0 mm i.d. × 35 mm length. Concerning the analytical column (1.0 mm i.d. × 250 mm), CAPCELL PAK C18 UG120, MG-II (particle size, 3 μm) and IF columns (1.8 μm) were tested. The CAPCELL PAK C18 IF column was selected as the analytical column with its high theoretical plate number. Combining these columns and solvents, a fully-automated online oxidation column-switching HPLC system was developed.
The present method was validated by checking the calibration line, intra-day precision and inter-day precision using the standard melatonin. The intra-day precision, inter-day precision and accuracy using the human plasma and saliva were also examined. The calibration line (y = 1.29x + 0.64, where x is the amount of injected melatonin (fmol), y is the fluorescence intensity (mV) of final detector) was linear from 500 amol to 50 fmol with a correlation coefficient greater than 0.9997. The intra-day precision and the inter-day precision of the standard melatonin were 0.86% (RSD, n = 5) and 4.07% (RSD, 5 days), respectively. The intra-day precision, inter-day precision and accuracy using endogenous melatonin in human plasma and saliva were also examined. As a result, the RSD values of the intra-day precision and the inter-day precision using human plasma were 9.95 and 8.63%, and those for human saliva were 2.44 and 4.83%, respectively. The accuracy of the melatonin measurement in human plasma and saliva using the present method was determined by comparing the slope of the calibration line and those of the standard lines constructed by adding 0.5, 1, 5, 10 and 50 fmol of melatonin to the human plasma or saliva.
The accuracy values were 106 and 103%, respectively. The lower limit of quantification and the lower limit of detection of melatonin using the present method were 500 amol (injection amount) and 200 amol (S/N = 3, injection amount), respectively.
Until now, various analytical methods, such as enzyme immunoassay, [18] [19] [20] [21] 28 GC-MS [22] [23] [24] and HPLC methods, [25] [26] [27] 29, 30 have been reported for the determination of melatonin. Enzymatic methods (both RIA and ELISA) are frequently used, and various assay kits are commercially available. However, enzymatic immunoassays are widely known to show crossreactions or non-specific bindings, [17] [18] [19] [20] [21] 28 especially for the determination of trace amounts of an analyte like melatonin. GC-MS methods with N-trimethylsilyl or pentafluoropropionic derivatization are sensitive, [22] [23] [24] however, both derivatization procedures require skillful techniques. Concerning HPLC, various methods combining an electrochemical detector, 25 a fluorescence detector 26 or MS 27, 29, 30 have been reported. However, the limit of detection of melatonin using these analytical methods are around 5 fmol/injection, and a 1 -5 mL blood sample is thus needed for the determination of melatonin. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Therefore, a more sensitive and selective analytical method is highly required in order to determine endogenous melatonin in a small drop (100 μL) of plasma/ serum. In the present method, the detected compound is 6-MOQMA, produced by the oxidative reaction of melatonin. The molar absorptivity and fluorescence quantum yield of this compound are 46300 [L mol -1 cm -1 ] and 0.31 (excitation at 245 nm), respectively. 33 The fluorescence intensity of 6-MOQMA is 6.8 times higher than that of melatonin, and the highly sensitive determination of melatonin could also be carried out due to the large shift between the excitation wavelength (245 nm) and the emission wavelength (380 nm). Furthermore, the newly developed fully-automated on-line oxidation columnswitching HPLC system consists of microbore-columns of Proteonavi (1.0 mm × 75 mm) for the purification of melatonin, Asahipak ODP 40-1T (1.0 mm × 35 mm) for the concentration of 6-MOQMA and CAPCELL PAK C18 IF (1.0 mm × 250 mm) for the final determination of 6-MOQMA. The lower limit of detection of melatonin using the present method is 200 amol/ injection and 10 -100 times more sensitive than those obtained by the already reported methods. In addition, the newly developed system is fully-automated, and reproducible results could be easily obtained without contamination.
Determination of endogenous melatonin in human plasma and saliva
As the application of the present fully-automated on-line oxidation column-switching HPLC system, endogenous melatonin values in human plasma and saliva were determined. For both the plasma and saliva, the endogenous melatonin was analyzed during the diurnal period and nocturnal period. Concerning the purification column used for the first step fractionation of melatonin, many interfering peaks were observed in all of the samples, and peak for melatonin could not be distinguished. On the other hand, a clear 6-MOQMA peak was observed on the analytical column after the purification and oxidation of melatonin. Figure 6 shows chromatograms of 6-MOQMA derived from melatonin in human plasma (blood was collected at 12:30 during the diurnal period, and 00:30 during the nocturnal period). Endogenous melatonin in human plasma showed a clear circadian rhythm; the concentration in human plasma was 8.1 fmol mL -1 in the diurnal period, and 59.7 fmol mL -1 in the nocturnal period. Figure 7 shows chromatograms of 6-MOQMA derived from melatonin in human saliva (samples were collected at 12:30 and 00:30).
Endogenous melatonin in human saliva also showed a clear circadian rhythm; the concentrations were 1.7 fmol mL -1 in the diurnal period and 23.0 fmol mL -1 in the nocturnal period. The amounts of melatonin in human saliva were approximately 40% of those in the plasma.
For the determination of endogenous melatonin in human plasma, various analytical methods, such as RIA, 18, 19 GC-MS, [22] [23] [24] HPLC-ECD 25 and HPLC-FD, 26 have been reported. The reported amounts of endogenous melatonin in human plasma are 5 -500 fmol mL -1 . In the present investigation, the value of melatonin was 8.1 fmol mL -1 in the diurnal period and 59.7 fmol mL -1 in the nocturnal period; these values were consistent with those reported in the literature. The already reported analytical methods require 1 -5 mL of human plasma, because the concentration of melatonin in human plasma is in the range of 5 -10 fmol mL -1 during the diurnal period. On the other hand, the newly developed fully-automated on-line oxidation column-switching HPLC system enables the determination of melatonin using only 100 μL of human plasma, even during the diurnal period. Therefore, based on the present method, a less invasive blood collection technique could be used to determine the melatonin rhythm in patients. Saliva is also a non-invasive clinical sample. However, collecting a few mL of saliva is practically difficult, and a sensitive analytical method is also required.
For the determination of endogenous melatonin in human saliva, RIA, 20 
ELISA
28 and HPLC-MS/MS 30 methods have been previously reported. The reported amounts of melatonin in human saliva are 15 -150 fmol mL -1 during the nocturnal period, and the values are 30 -40% of those in the plasma. 35, 36 In the present investigation, we have determined the endogenous melatonin in human saliva; the amount was 1.7 fmol mL -1 in the diurnal period and 23.0 fmol mL -1 in the nocturnal period. The amount of melatonin in human plasma was 8.1 fmol mL -1 in the diurnal period and 59.7 fmol mL -1 in the nocturnal period, therefore, the amounts of melatonin in human saliva determined in the present study were approximately 40% of those in the plasma. The results obtained in the present study are consistent with those reported in the literature. Concerning the amount of saliva, only 300 μL of saliva was used in the present study. It is much easier to collect 300 μL of saliva than collecting 3 mL of saliva, indicating that the newly-developed HPLC system is useful for the analysis of melatonin in clinical samples.
Conclusions
In the present investigation, we have established a fullyautomated on-line oxidation column-switching HPLC system for the determination of melatonin. The HPLC system was validated, and endogenous melatonin in a small drop (100 μL) of human plasma was successfully determined. Endogenous melatonin in a small volume (300 μL) of human saliva could also be determined. The melatonin rhythm of each patient is expected to be clarified for the diagnosis and treatment of rhythm disorders, and also for clinical use in chronotherapy. The present HPLC system is a useful tool for monitoring endogenous melatonin in small volumes of human physiological fluids, and the clinical applications are currently in progress.
